| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4655b70cbfba352025a1d2393b449e77 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-451 |
| filingDate |
1990-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ad7d1e50964f97fca308dee6910b75f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e772f4ba409f297bf7389150dc4f24f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe9ec5446aa2462e51e34d16b9afb4dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b4feedb4e3210d3bf8fc529fc68f912
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1dde716fc9d38dba622fe6ee87d2bd1e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_146d584ccacf94f1793596edfc644b31 |
| publicationDate |
1991-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H03170428-A |
| titleOfInvention |
Curing agent for psychasthenia |
| abstract |
PURPOSE: To obtain a curing agent for human psychasthenia having high miscibility to a γ-receptor and useful for curing of a human neurological diseases by containing specific compounds. CONSTITUTION: This curing agent contains a pure optical isomer or a mixture of optical isomers in a free base state or a pharmaceutically allowable acid added salt state of a compound of the formula (R<1> is a halogen or hydroxy; R<2> is H or methyl; R<3> is H or a halogen) in an amount effective for anti- neurological diseases. As the compound of the formula, (±)erythro-α-(4- hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidine ethanol is exemplified. The compound of the formula is used in a formulation of tablet or capsule and within a range of 1-120mg of an active substance by combinedly using with a suitable excipient. |
| priorityDate |
1989-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |